Creation of Porous Fibers for Adsorbing Pathogenic Substances in Intractable Diseases
Key facts
- Creation of Porous Fibers for Adsorbing Pathogenic Substances in Intractable Diseases
- Toray Industries has developed technology to control the pore size of PMMA porous fibers up to 1,000nm. This enables selective removal of large-molecular-weight pathogenic substances for intractable diseases. The company aims for early practical application in blood purification therapies.
- Source: PR Times
- Date: March 28, 2026
Direct answer
Toray Industries has developed technology to control the pore size of PMMA porous fibers up to 1,000nm. This enables selective removal of large-molecular-weight pathogenic substances for intractable diseases. The company aims for early practical application in blood purification therapies.
- Citation
- Creation of Porous Fibers for Adsorbing Pathogenic Substances in Intractable Diseases (March 28, 2026), PR Times
- Source
- PR Times
- Date
- March 28, 2026
Toray Industries has developed technology to control the pore size of PMMA porous fibers up to 1,000nm. This enables selective removal of large-molecular-weight pathogenic substances for intractable diseases. The company aims for early practical application in blood purification therapies.
📋 Article Processing Timeline
- 📰 Published: March 28, 2026 at 02:59
- 🔍 Collected: March 28, 2026 at 21:59 (19h 0m after Published)
- 🤖 AI Analyzed: April 15, 2026 at 05:34 (415h 35m after Collected)
FAQ
What is the key feature of the developed fibers?
They allow for arbitrary control of pore size up to 1,000nm while maintaining fiber strength, enabling selective adsorption of large-molecular-weight pathogenic substances.
What are the main applications?
They are aimed at being used as a new blood purification treatment option for intractable diseases such as autoimmune disorders and cancer.
What are the key facts in this article?
Toray Industries has developed technology to control the pore size of PMMA porous fibers up to 1,000nm. This enables selective removal of large-molecular-weight pathogenic substances for intractable diseases. The company aims for early practical application in blood purification therapies.